Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

7 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Follow-Up - Conjunctival Exam; Corneal Exam; Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status

- 09.03.20 - 1 Formular, 7 Itemgruppen, 69 Datenelemente, 1 Sprache
Itemgruppen: Conjunctival Exam , Corneal Exam , Anterior Chamber Exam , Lens Opacity , Fundus Exam , Optical Coherence Tomography , Fundus photographs and fluorescein angiography status
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Week 52 - Conjunctival Exam; Corneal Exam; Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status

- 08.03.20 - 1 Formular, 7 Itemgruppen, 69 Datenelemente, 1 Sprache
Itemgruppen: Conjunctival Exam , Corneal Exam , Anterior Chamber Exam , Lens Opacity , Fundus Exam , Optical Coherence Tomography , Fundus photographs and fluorescein angiography status
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Week 8; 12; 16; 20; 28; 32; 36; 40; 44; 48 - Conjunctival Exam; Corneal Exam; Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status

- 06.03.20 - 1 Formular, 7 Itemgruppen, 69 Datenelemente, 1 Sprache
Itemgruppen: Conjunctival Exam , Corneal Exam , Anterior Chamber Exam , Lens Opacity , Fundus Exam , Optical Coherence Tomography , Fundus photographs and fluorescein angiography status
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Week 4 - Conjunctival Exam; Corneal Exam; Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status

- 02.03.20 - 1 Formular, 7 Itemgruppen, 69 Datenelemente, 1 Sprache
Itemgruppen: Conjunctival Exam , Corneal Exam , Anterior Chamber Exam , Lens Opacity , Fundus Exam , Optical Coherence Tomography , Fundus photographs and fluorescein angiography status
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Unscheduled - Conjunctival Exam; Corneal Exam; Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status; Ranibizumab Re-Injection

- 17.02.20 - 1 Formular, 8 Itemgruppen, 73 Datenelemente, 1 Sprache
Itemgruppen: Conjunctival Exam , Corneal Exam , Anterior Chamber Exam , Lens Opacity , Fundus Exam , Optical Coherence Tomography , Fundus photographs and fluorescein angiography status , Ranibizumab Re-Injection
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Day 1 - Conjunctival Exam; Corneal Exam; Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status; Randomisation Number; Treatment Regimen; Investigational Product (Eye Drops) - First Dose Date/ Time, Dispensed, Administration

- 14.02.20 - 1 Formular, 12 Itemgruppen, 78 Datenelemente, 1 Sprache
Itemgruppen: Conjunctival Exam , Corneal Exam , Anterior Chamber Exam , Lens Opacity , Fundus Exam , Optical Coherence Tomography , Fundus photographs and fluorescein angiography status , Randomisation Number, Treatment Regimen , Investigational Product (Eye Drops) - First Dose Date/ Time , Investigational Product (Eye Drops) - Dispensed, Eye Drop Administration
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Screen - Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status

- 24.01.20 - 1 Formular, 5 Itemgruppen, 41 Datenelemente, 1 Sprache
Itemgruppen: Anterior Chamber Exam, Lens Opacity, Fundus Exam, Optical Coherence Tomography, Fundus photographs and fluorescein angiography status
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video